Catalyst Crew Technologies Corp. (OTC: CCTC) announced the assignment of three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A., as part of a broader strategy to consolidate intellectual property and support global expansion. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies CardioAI, PulmoAI, and NeuroAI, which are designed for data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
The assignment aligns the company's IP with its operating structure, positioning the subsidiary as the primary development and commercialization vehicle for its technology platform in Latin America. The company believes this move enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion. Additionally, Catalyst Crew Technologies intends to pursue broader IP protection in other jurisdictions to support long-term platform development and international deployment.
Dr. Kevin Rodan Levy stated, 'Aligning our intellectual property within our operating structure is an important step as we continue building our platform. Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.'
The company continues to advance its digital health and AI platform, focusing on scalable solutions including telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics to improve access, efficiency, and care coordination. For more information, visit https://catalystcrewai.com or review SEC filings at www.sec.gov.
This strategic IP assignment underscores Catalyst Crew Technologies' commitment to building a robust foundation for its AI-driven healthcare solutions in emerging markets. By consolidating patents at the operating level, the company aims to streamline development and commercialization efforts while positioning itself for potential partnerships and licensing deals. The move also reflects a proactive approach to protecting proprietary technologies as the company expands its footprint beyond Latin America.
